Keyphrases
Immunogenicity
98%
ChAdOx1 nCoV-19
92%
COVID-19
89%
Antibody Response
64%
COVID-19 Vaccine
54%
BNT162b2
52%
Vaccination
45%
Randomized Controlled Trial
43%
Reactogenicity
36%
Two-dose
35%
AZD1222
35%
Virus
34%
Anthrax Vaccine
34%
Immune Response
33%
Neutralizing Antibodies
31%
Second Dose
29%
Geometric Mean
28%
Third Dose
28%
Randomized Trial
26%
Ferret
26%
ChAdOx1 nCoV-19 Vaccine
24%
Vaccine Response
24%
Chad
24%
Booster Dose
23%
Ratio of Means
23%
Influenza Virus
22%
T Cell Response
22%
Bacillus Anthracis
21%
Pertussis
21%
SARS-CoV-2 Infection
21%
Humoral Immune Response
21%
SARS-CoV-2 Vaccine
17%
Monkeypox Virus
17%
Confidence Interval
17%
Cellular Immune Response
17%
Vaccine Effectiveness
16%
BNT162b2 Vaccine
16%
Virus Neutralization
16%
Multiplex Immunoassay
16%
Neurotoxin
15%
Geometric Mean Concentration
13%
Prime-boost
13%
ChAdOx1
13%
Revaccination
13%
Convalescent
13%
Cellular Response
13%
Older People
12%
Enzyme-linked Immunosorbent Assay (ELISA)
12%
Blood Samples
12%
Spike Protein
12%
Immunology and Microbiology
Severe Acute Respiratory Syndrome Coronavirus 2
100%
Immunogenicity
68%
Antibody Response
62%
COVID-19
56%
Spike
43%
Immune Response
42%
Humoral Immunity
32%
Virus
32%
Neutralization
32%
Anthrax Vaccine Adsorbed
29%
Neutralizing Antibody
27%
Mustela Putorius Furo
27%
Adoptive Immunity
26%
Immunoglobulin G
25%
T Cell
24%
Influenza Virus
23%
Influenza
23%
Booster Dose
22%
Monkeypox Virus
21%
Antibody Titer
19%
Immunoassay
19%
Pertussis Toxin
17%
Bacillus Anthracis
16%
Meningococcal Vaccine
15%
ELISA
14%
Low Drug Dose
14%
Virus Antigen
14%
Hemagglutinin
13%
Viral Protein
13%
Serotype
13%
Influenza Vaccine
12%
Influenzavirus A
12%
Viral Disease
12%
Viral Vector
11%
Haemophilus Influenzae Type B
11%
Defective Interfering Particle
10%
Vaccine Adjuvant
10%
Macaca fascicularis
10%
Omicron Coronavirus Variant
10%
Tetanus Vaccine
10%
Bacterium Antibody
10%
Viral Shedding
10%
Lineages
10%
Lethal Gene
9%
Peptides
8%
Virus Neutralization
8%
Pertactin
8%
Serum (Blood)
7%
Plaque-Forming Unit
7%
Modified Vaccinia Ankara
7%
Medicine and Dentistry
Severe Acute Respiratory Syndrome Coronavirus 2
84%
Immunogenicity
70%
Infection
61%
COVID-19 Vaccine
48%
COVID-19
47%
Antibody Response
46%
Booster Dose
34%
Immune Response
33%
Randomized Controlled Trial
31%
Neutralizing Antibody
30%
Messenger RNA
30%
Single Drug Dose
26%
Humoral Immunity
23%
Cellular Immunity
22%
Neutralization
21%
Reactogenicity
19%
Clinical Trial
19%
Enzyme Linked Immunosorbent Assay
15%
Vaccine Efficacy
14%
COVID-19 Vaccination
14%
T Cell
13%
T-Cell Response
12%
Medicine
11%
Adverse Event
11%
Virus Vector
11%
mRNA Vaccine
11%
Immunoassay
11%
Vaccine Adjuvant
10%
Viral Protein
10%
Noninferiority Trial
10%
Nucleic Acid Amplification
10%
Diseases
9%
Drug Dose Regimen
9%
Virus Neutralization
7%
Pertussis
7%
Arm
7%
Interim Analysis
6%
Adaptive Immunity
6%
Antibody Generation
6%
Virus
5%
Virus Particle
5%
Pooled Analysis
5%
Meningococcus Vaccine
5%
Phagocytosis
5%
Quantitative Assay
5%
Primary Infection
5%
Influenza Vaccine
5%
Group Trial
5%
Cross Sectional Study
5%
Neisseria meningitidis
5%